Suppr超能文献

住院患者腹腔穿刺术的安全性

Safety of paracentesis in inpatients.

作者信息

Duggal P, Farah K F, Anghel G, Marcus R J, Lupetin A R, Babich M M, Sandroni S E, McGill R L

机构信息

Division of Gastroenterology, West Penn Allegheny Health System, Allegheny General Hospital, Pittsburgh, PA, USA.

出版信息

Clin Nephrol. 2006 Sep;66(3):171-6. doi: 10.5414/cnp66171.

Abstract

INTRODUCTION

Prior research has suggested that paracentesis is free from complications such as acute renal failure (ARF) providing albumin is administered. Actual safety of paracentesis > 1,000 ml was assessed at a tertiary care hospital.

METHODS

300 inpatient paracenteses performed between 12/99 and 4/04 were identified by coding records, of which 40 procedures were excluded due to lack of pre- or post-procedure lab values. Charts were reviewed for serum creatinine (Scr) before and after procedures, ascites volume, and clinical outcomes.

RESULTS

44 deaths occurred after 260 paracenteses (16.9%). Among 33 patients with ARF, 13 (39.4%) died. Only 31/227 patients without ARF (13.7%) died (p < 0.001). Serum creatinine (Scr) > 1.6 mg/dl prior to paracentesis predicted a 22.5% rate of ARF, compared to 8% for Scr < 1.0 (p = 0.002). ARF increased as volume increased (9.9%, 12.4%, and 14.9%, for volumes of < 2,300, 2,300 - 3,200, and > 3,200 ml) but this trend did not have statistical significance (p = 0.426). ARF occurred in 11/69 (15.9%) of patients receiving albumin, compared to 22/191 (11.5%) of patients who did not (p = 0.462).

CONCLUSIONS

Paracentesis in inpatients has significant rates of ARF and death. Scr > 1.6 prior to paracentesis predicts an increased rate of ARF. Development of ARF is associated with an increased rate of death. No advantage was demonstrated with administration of albumin. Pre- and post-paracentesis labwork should be routine in inpatients.

摘要

引言

先前的研究表明,只要给予白蛋白,腹腔穿刺术就不会出现诸如急性肾衰竭(ARF)等并发症。一家三级护理医院对超过1000毫升的腹腔穿刺术的实际安全性进行了评估。

方法

通过编码记录识别出1999年12月至2004年4月期间进行的300例住院患者腹腔穿刺术,其中40例因缺乏术前或术后实验室检查值而被排除。查阅病历以获取术前和术后的血清肌酐(Scr)、腹水量及临床结果。

结果

260例腹腔穿刺术后发生44例死亡(16.9%)。在33例急性肾衰竭患者中,13例(39.4%)死亡。在227例无急性肾衰竭的患者中,仅31例(13.7%)死亡(p<0.001)。腹腔穿刺术前血清肌酐(Scr)>1.6毫克/分升预测急性肾衰竭发生率为22.5%,而Scr<1.0时为8%(p=0.002)。急性肾衰竭发生率随腹水量增加而升高(腹水量<2300毫升、2300 - 3200毫升和>3200毫升时分别为9.9%、12.4%和14.9%),但该趋势无统计学意义(p=0.426)。接受白蛋白治疗的患者中有11/69例(15.9%)发生急性肾衰竭,未接受白蛋白治疗的患者中有22/191例(11.5%)发生急性肾衰竭(p=0.462)。

结论

住院患者腹腔穿刺术有显著的急性肾衰竭发生率和死亡率。腹腔穿刺术前Scr>1.6预测急性肾衰竭发生率增加。急性肾衰竭的发生与死亡率增加相关。未证明给予白蛋白有优势。腹腔穿刺术前和术后的实验室检查对住院患者应常规进行。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验